Splisense Ltd.
- Address
- Minrav Bldg, Floor 1st, Haddasah Ein Karem
Sponsor Overview
Specializations
Respiratory Genetics and Cystic Fibrosis
Research activity is centered on cystic fibrosis, with attention to the underlying genetic and respiratory dimensions of the disease. The clinical focus includes treatment strategies intended for patients living with chronic airway disease and inherited pulmonary dysfunction.
- Cystic fibrosis
- Inherited respiratory disease
- Airway pathology
Clinical interest extends to therapies designed for inhaled delivery in the management of respiratory symptoms associated with this condition.
Inhalation Therapy and Pulmonary Delivery
The sponsor’s therapeutic work includes medicines administered by inhalation, reflecting a focus on direct treatment of the airways and lungs. This area is relevant to muco-obstructive lung disease and other conditions requiring localized pulmonary exposure.
- Inhaled therapeutics
- Pulmonary drug delivery
- Airway-targeted treatment
Development interest is directed toward therapies that can be evaluated for tolerability and pharmacokinetics in patients with chronic lung disease.
Safety, Tolerability, and Pharmacokinetics
Clinical research includes assessment of safety and tolerability alongside pharmacokinetic behavior in people with cystic fibrosis. These interests support the evaluation of how inhaled treatments are handled in the body and how they are received by patients with respiratory impairment.
- Safety evaluation
- Tolerability assessment
- Pharmacokinetics
The therapeutic emphasis is on understanding treatment exposure and patient response in a pulmonary disease setting.
Preliminary Efficacy in Rare Disease
Research also addresses early signals of efficacy in a rare genetic disorder with major respiratory burden. The clinical landscape is shaped by the need for therapies that may improve disease-related outcomes in cystic fibrosis.
- Preliminary efficacy
- Rare disease therapeutics
- Genetic lung disorder
This area remains closely tied to treatment development for patients with chronic airway disease and inherited mucus clearance impairment.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Cystic Fibrosis Patients with 3849+10 Kb C->T Mutation |  Czechia France Germany Hungary Italy Lithuania Poland Slovakia Spain | Not Yet Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 14 sites across their trial portfolio.
Therapeutic Focus
- 1.Respiratory Tract Diseases1 trial277 other sponsors
Partnered Research Centres
14 centres- Address
- Via Consolare Valeria N 1, 98124 Messina
- Address
- Via Santa Sofia 78, 95123 Catania
- Address
- 80 Avenue Augustin Fliche, 34295 Montpellier
- Address
- V Uvalu 84/1, Motol, 150 00 Prague
- Address
- Nám. L. Svobodu 1, 975 17 Banská Bystrica
- Address
- Via Francesco Sforza 28, 20122 Milan
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Splisense Ltd..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.